Is it time to switch to bivalirudin for ECMO anticoagulation?

Area of Science:

• Cardiology
• Critical Care Medicine
• Pharmacology

Background:

• Unfractionated heparin has been the standard anticoagulant for extracorporeal membrane oxygenation (ECMO).
• Bivalirudin, a direct thrombin inhibitor, is increasingly used as an alternative anticoagulant in ECMO.
• Standardized definitions for bleeding and thrombosis in ECMO are lacking, complicating direct comparisons.

Purpose of the Study:

• To systematically review and compare the efficacy and safety of heparin versus bivalirudin as anticoagulants in ECMO.
• To summarize findings from comparative studies, meta-analyses, and review articles on heparin and bivalirudin in ECMO.
• To provide guidance on anticoagulant selection and monitoring for ECMO patients.

Main Methods:

• Systematic review adhering to PRISMA guidelines.
• Inclusion of 16 comparative studies and 8 meta-analysis/review articles.
• Literature search from January 2011 to May 2023, focusing on direct comparisons of heparin and bivalirudin in ECMO.

Main Results:

• Overall, no statistically significant difference in bleeding or thrombosis rates between heparin and bivalirudin for ECMO.
• Some studies indicated a statistical advantage for bivalirudin in reducing major bleeding and thrombosis.
• Bivalirudin use was associated with a reduced need for transfusions in certain studies.

Conclusions:

• Heparin and bivalirudin demonstrate comparable safety and efficacy profiles for anticoagulation during ECMO.
• Bivalirudin may offer benefits in reducing major bleeding and transfusion requirements in select ECMO cases.
• Careful selection and monitoring of anticoagulants are crucial for optimal ECMO management.